U.S. Food and Drug Administration (FDA)

Sun Pharma announced U.S. FDA approval for ILUMYA to treat adults with active psoriatic arthritis, expanding its use beyond plaque psoriasis. The approval is supported by Phase 3 INSPIRE-1 and INSPIRE